Zane Lee T, Hughes Matilda H, Shakib Sepehr
Anacor Pharmaceuticals, Inc., 1020 E Meadow Cir, Palo Alto, CA, 94303, USA.
Department of Clinical Pharmacology, The Royal Adelaide Hospital, Adelaide, SA, Australia.
Am J Clin Dermatol. 2016 Oct;17(5):519-526. doi: 10.1007/s40257-016-0204-6.
Inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis often present in sensitive and thin-skinned areas that are at higher risk for topical treatment-related skin irritation (e.g., burning, stinging).
Our objective was to address the need for topical treatments that can be safely applied to these areas. We assessed the local tolerability of crisaborole topical ointment when applied to sensitive and thin-skinned areas of healthy volunteers.
In this phase I, randomized, double-blind, vehicle-controlled, single-center study, 32 subjects were randomized 3:1 to twice-daily application of crisaborole topical ointment, 2 %, (n = 24) or vehicle ointment (n = 8) for 21 days to 13 anatomic skin areas, including the face/hairline, genitals, extensor, and intertriginous areas. The primary endpoint was assessment of the frequency and severity of local tolerability symptoms (burning/stinging, erythema, and pruritus) using the Local Tolerability Scale.
Overall, 98.8 % of all tolerability assessments had a grade of 0 (no signs/symptoms of irritation) and 0.1 % had a grade >1 (mild); no differences were observed in the frequency of local tolerability scores between treatment groups. The total frequency of local tolerability assessments graded >0 (none) was lower across all application sites with crisaborole ointment (0.0-2.2 %) than with vehicle ointment (2.4-7.1 %). Local tolerability did not change over time, and was comparable between sensitive and nonsensitive skin areas.
Crisaborole ointment application to sensitive skin areas was well tolerated in healthy volunteers, supporting its potential role as a topical treatment alternative for patients with AD or psoriasis.
特应性皮炎(AD)和银屑病等炎症性皮肤病常出现在敏感且皮肤薄的区域,这些区域发生局部治疗相关皮肤刺激(如灼烧、刺痛)的风险更高。
我们的目标是满足对可安全应用于这些区域的局部治疗的需求。我们评估了克立硼罗外用软膏应用于健康志愿者敏感且皮肤薄的区域时的局部耐受性。
在这项I期、随机、双盲、赋形剂对照、单中心研究中,32名受试者按3:1随机分为两组,分别每日两次外用2%克立硼罗软膏(n = 24)或赋形剂软膏(n = 8),共21天,涂抹于13个解剖学皮肤区域,包括面部/发际线、生殖器、伸侧和间擦部位。主要终点是使用局部耐受性量表评估局部耐受性症状(灼烧/刺痛、红斑和瘙痒)的频率和严重程度。
总体而言,所有耐受性评估中有98.8%的评分为0级(无刺激迹象/症状),0.1%的评分为>1级(轻度);治疗组之间局部耐受性评分的频率未观察到差异。与赋形剂软膏(2.4 - 7.1%)相比,克立硼罗软膏在所有涂抹部位的局部耐受性评估分级>0(无)的总频率更低(0.0 - 2.2%)。局部耐受性未随时间变化,在敏感和非敏感皮肤区域之间相当。
在健康志愿者中,克立硼罗软膏应用于敏感皮肤区域耐受性良好,支持其作为AD或银屑病患者局部治疗替代方案的潜在作用。